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The mechanisms of CD4 T-cell depletion during human immunodeficiency virus type 1 (HIV-1) infection
remain incompletely characterized. Of particular importance is how CD4 T cells are depleted within the
lymphoid organs, including the lymph nodes and thymus. Herein we characterize the pathogenic mechanisms
of an envelope from a rapid progressor (R3A Env) in the NL4-3 backbone (NL4-R3A) which is able to efficiently
replicate and deplete CD4 thymocytes in the human fetal-thymus organ culture (HF-TOC). We demonstrate
that uninterrupted replication is required for continual thymocyte depletion. During depletion, NL4-R3A
induces an increase in thymocytes which uptake 7AAD, a marker of cell death, and which express active
caspase-3, a marker of apoptosis. While 7AAD uptake is observed predominantly in uninfected thymocytes
(p24), active caspase-3 is expressed in both infected (p24) and uninfected thymocytes (p24). When added
to HF-TOC with ongoing infection, the protease inhibitor saquinavir efficiently suppresses NL4-R3A replica-
tion. In contrast, the fusion inhibitors T20 and C34 allow for sustained HIV-1 production. Interestingly, T20
and C34 effectively prevent thymocyte depletion in spite of this sustained replication. Apoptosis of both p24
and p24 thymocytes appears to be envelope fusion dependent, as T20, but not saquinavir, is capable of
reducing thymocyte apoptosis. Together, our data support a model whereby pathogenic envelope-dependent
fusion contributes to thymocyte depletion in HIV-1-infected thymus, correlated with induction of apoptosis in
both p24 and p24 thymocytes.
Infection with human immunodeficiency virus type 1 (HIV-1)
is characterized by progressive depletion of CD4 T cells and
eventual progression to AIDS. The mechanisms responsible
for CD4 T-cell depletion are still not fully understood. While
it was initially thought that direct infection of target cells was
responsible for T-cell depletion (26, 55), subsequent observa-
tions suggested a contribution of indirect or bystander killing
of uninfected cells (reviewed in reference 24). Throughout
infection, less than 1% of peripheral target cells are infected
(8, 11), while most apoptotic T cells in lymphoid organs of
infected children and simian immunodeficiency virus (SIV)-
infected macaques are not productively infected (1, 19). In-
creased bystander cell death during chronic infection may rep-
resent activation-induced cell death consistent with an immune
response to a chronic pathogen (24, 42). Because lack of im-
mune activation in conjunction with high viral loads is ob-
served in sooty mangabees that do not develop disease (9, 32,
43), bystander activation likely plays a role in human progres-
sion to AIDS.
In contrast to chronic infection, acute infection is charac-
terized by massive and rapid depletion of CD4 memory T
cells, particularly in the gut-associated lymphoid tissue, that
is thought to occur primarily through direct viral infection
and lysis (7, 23, 25, 51, 52). Greater understanding of the
mechanisms by which transmitted viruses mediate T-cell
depletion during acute infection will improve our under-
standing of HIV-1 pathogenesis. In particular, the dynamics
and mechanisms of cell depletion in solid lymphoid organs,
including the gut, lymph nodes, spleen, and thymus, require
further elucidation.
A number of in vivo and ex vivo organ systems have been
developed as models to study HIV-1-induced CD4 T-cell
depletion. These peripheral blood lymphocyte include the SCID-
hu, SCID-hu thymus/liver, lymph node organ culture (or tonsil
histoculture) and the human fetal thymus-organ culture (HF-
TOC). All offer primary cell microenvironments that do not re-
quire exogenous stimulation for replication of primary HIV-1
isolates (18, 21, 22) and in some cases are refractory to replication
by tissue culture-adapted isolates (40, 49). These systems differ
from human infection in that they cannot support an adaptive
immune response against HIV. Rather, they serve as models for
what might happen in lymphoid organs in vivo if innate immunity
was the lone defense against viral replication, such as during acute
infection. Evidence from these models has indicated a prominent
role for bystander apoptosis (31, 41) and direct viral lysis (22, 33)
as mechanisms of T-cell depletion.
The thymus is an apoptotic factory designed to produce new
naı̈ve T cells and eliminate auto- or nonreactive T cells by
apoptosis. It is a target for HIV-1 infection, and its disruption
has been correlated with disease progression in pediatric pa-
tients (13, 34, 53). Furthermore, recovery of thymic function
after highly active antiretroviral therapy has been correlated
with immune recovery (15–17, 36). Thymic sections from HIV-
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1-infected humans or SIV/SHIV-infected macaques show in-
creased apoptosis, suggesting that HIV-1 can either directly or
indirectly hasten thymocyte depletion (28, 29, 45, 47, 56). A
number of studies addressing mechanisms of CD4 thymocyte
death in the thymus organ have indicated that both direct viral
lysis and bystander apoptosis occur during thymocyte depletion
(5, 6, 30, 48). Whether bystander apoptosis is specifically in-
duced by HIV-1 or occurs nonspecifically after the bulk of
lysis-induced thymocyte depletion remains a subject of ongoing
debate.
Herein we characterize the pathogenic mechanisms of an
envelope from a rapid progressor (R3A Env) in the NL4-3
backbone (NL4-R3A) which is able to mediate efficient rep-
lication and depletion of CD4 thymocytes in the human
fetal-thymus organ culture (HF-TOC). Notably, the R3A
Env is capable of using both CCR5 and CXCR4 as entry
coreceptors (37, 38). We demonstrate that uninterrupted
replication is required for continual thymocyte depletion.
During depletion, NL4-R3A induces an increase in thymo-
cytes which uptake 7AAD, a marker of cell death, and
express active caspase-3, a marker of apoptosis. While
7AAD is observed predominantly in uninfected thymocytes
(p24), active caspase-3 is expressed in both infected (p24)
and uninfected thymocytes (p24). While the anti-HIV drug
saquinavir efficiently suppresses ongoing NL4-R3A replica-
tion, the fusion inhibitors T20 and C34 allow for sustained
HIV-1 production. Interestingly, T20 and C34 effectively
prevent thymocyte depletion in spite of this sustained rep-
lication. Apoptosis of both p24 and p24 thymocytes ap-
pears to be envelope fusion dependent, as the fusion inhib-
itors T20 and C34, but not the protease inhibitor saquinavir,
are capable of reducing thymocyte apoptosis. These data are
the first to describe Env-specific and fusion-dependent in-
duction of apoptosis in a relevant lymphoid organ model.
MATERIALS AND METHODS
Viral isolates and drugs. The NL4-R3A and NL4-R3B viruses have been
previously described (38). Saquinavir (National Institute of Allergy and Infec-
tious Diseases [NIAID], National Institutes of Health [NIH]) was dissolved in
dimethyl sulfoxide at a 10 mM concentration and was used in HF-TOC at a 1 M
concentration. Peptides T20 and C34 were synthesized by a standard solid-phase
9-fluorenylmethoxy carbonyl method at the MicroChemistry Laboratory of the
New York Blood Center. The peptides were purified to homogeneity (95%
purity) by high-performance liquid chromatography and identified by laser de-
sorption mass spectrometry (PerSeptive Biosystems, Framingham, MA). T20 was
reconstituted at a stock concentration of 0.5 mg/ml in 50% ethanol and was used
at a concentration of 10 to 50 g/ml in HF-TOC. C34 was reconstituted at a stock
concentration of 1 mg/ml in phosphate-buffered saline and was used at a con-
centration of 10 g/ml in HF-TOC.
Fluorescent-activated cell sorter (FACS) analysis. CD4-PE and CD8-TC
(Caltag) were used for surface staining of thymocytes. 7AAD was used to stain
dead thymocytes prior to intracellular staining. The Cytofix/Cytoperm kit (BD
Biosciences) was used for intracellular staining with active caspase-3–phyco-
erythrin (BD Biosciences) and anti-p24 KC57-fluorescein isothiocyanate (FITC)
(Beckman Coulter).
Viral quantitation. A p24 enzyme-linked immunosorbent assay (ELISA) kit
(Perkin-Elmer or AIDS Vaccine Program, NIH) was used to detect Gag present
in the HF-TOC supernatant.
Human fetal-thymus organ culture. The procedure for HF-TOC has been
previously described (6, 38, 40). Briefly, human fetal thymuses (19 to 24 gesta-
tional weeks) were dissected into 2-mm3 fragments using a dissecting micro-
scope. Five to six fragments were placed on organotypic culture membranes
(Millipore) underlaid by media (RPMI with 10% fetal bovine serum, 50 g of
streptomycin/ml, 50 U of penicillin G/ml, 1 minimal essential medium vitamin
solution [Gibco-BRL], 1 insulin-transferrin-sodium selenite medium supple-
ment [Sigma], and beta-mercaptoethanol) in 6-well tissue culture plates. An
equal amount of virus (100 to 800 IU) in 15 l of supernatant from infected
phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs) or
mock supernatant was applied to each fragment. Viral and mock supernatants
produced from the same PBMC donor were used within each experiment. Frag-
ments were cultured at 37°C in 5% CO2 for up to 12 days with daily changes of
culture media. Thymocytes were teased out of the fragments using pestles
(Bellco Co.) and were stained as described above.
Immunofluorescence. Thymus fragments were fixed in formaldehyde and em-
bedded in paraffin. Sections were probed with rabbit anti-active caspase-3 (Pro-
mega, Madison, WI) and/or HIV p24 monoclonal antibody (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH), followed by the
secondary antibodies Fluor 546-conjugated goat anti-rabbit immunoglobulin G
(IgG) and/or Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad,
CA). Stained slides were analyzed by confocal microscopy.
Statistical analysis. Trend line significance was tested with simple linear re-
gression. A P value of less than 0.05 was considered significant. Differences in
“mock/no drug versus treatment” trends were tested by the significance of the
regression coefficient of the interaction term between the “mock/no drug and
treatment” variables. A P value of less than 0.05 was considered significant. All
analyses were performed using SAS statistical software (version 9.1; SAS Insti-
tute, Inc.).
RESULTS
Depletion of thymocytes requires ongoing HIV-1 replication.
To assess mechanisms of HIV-1-induced thymocyte deple-
tion, we analyzed a pathogenic virus (NL4-R3A) which ef-
ficiently depletes CD4 thymocytes in the HF-TOC. For
comparison, we also studied a related virus (NL4-R3B)
which is less pathogenic (37, 38). The NL4-R3A and NL4-
R3B viruses contain env genes transmitted to a rapid pro-
gressor cloned into the NL4-3 backbone, but they lack nef
(37, 38). Both R3A and R3B Env are capable of using CCR5
and CXCR4 as entry coreceptors. During a typical infection
with NL4-R3A, there is a reduction in the percentage of live
cells gated by forward and side scatter light profiles and the
percentage of live thymocytes which are CD4 (Fig. 1A and
B). This loss of thymocytes typically occurs rapidly around 8
to 10 days postinfection (dpi) at the peak of viral infection,
likely after a threshold of viral replication is reached (10,
38). In contrast, live cell and CD4 thymocyte depletion
during infection with NL4-R3B occur at a much slower rate
(Fig. 1A and B).
To understand whether thymocyte depletion during infec-
tion is dependent upon continual viral replication, we added
the antiviral drug saquinavir during infection, which blocks
HIV-1 protease function and virion maturation. Notably, the
dose used was sufficient to completely inhibit NL4-R3A infec-
tion of HF-TOC when added at the time of initial infection
(data not shown).
Daily addition of saquinavir starting at 6 dpi, before the
peak in viral replication and depletion, resulted in preven-
tion of CD4 thymocyte depletion observed at 10 dpi (Fig.
1C). When saquinavir was added at 8 dpi at the peak of viral
replication and depletion, there was still a drop in CD4
percentage at 10 dpi, but this depletion was attenuated
relative to no drug (Fig. 1D). Furthermore, there was no
subsequent depletion of CD4 thymocytes at 12 dpi. To-
gether, these data suggest that cell death continues in part
after the addition of saquinavir, followed by complete inhi-
bition of subsequent CD4 thymocyte depletion. Inhibition
of replication, even during the peak of depletion, is suffi-
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cient to rescue at least some remaining thymocytes from cell
death, indicating that continual viral replication is necessary
for continued thymocyte depletion.
Depletion of CD4 thymocytes is accompanied by an in-
crease in the frequency of 7AAD cells, the majority of which
are not productively infected. We next determined the fre-
quency of dead cells in the scatter-defined gate using 7AAD, a
dye that stains cells with permeable membranes. We addition-
ally stained for intracellular p24 to delineate thymocytes which
are productively infected. Figure 2A shows a representative
plot at 9 and 12 dpi. Infection with NL4-R3A is accompanied
by an increase in 7AAD thymocytes and a large number of
infected cells but little overlap between the two populations.
An analysis of multiple HF-TOC assays with multiple donor
thymuses indicates that the frequency of 7AAD cells in-
creases around 9 to 10 dpi at the time of maximal thymocyte
depletion but occurs predominantly in NL4-R3A-infected HF-
TOC, not NL4-R3B-infected HF-TOC (Fig. 2B). Further-
more, the increase in 7AAD positivity occurs predominantly in
p24 thymocytes (Fig. 2C). Even at 11 to 12 dpi, when many
cells are infected and dying, there is no significant detection of
p24 7AAD thymocytes. Together, these data indicate that
infection with NL4-R3A increases the frequency of 7AAD
thymocytes only in the p24 population. Infected thymocytes
FIG. 1. CD4 thymocyte depletion is dependent on sustained viral replication. (A and B) Thymocytes from mock-, NL4-R3A-, and NL4-
R3B-infected HF-TOC were analyzed using flow cytometry for forward and side scatter (% gated live) (A) and expression of CD4 on cells which
were gated live (B). Shown are data from at least seven independent experiments. (, P  0.05 for the NL4-R3A trend line relative to mock and
NL4-R3B.) (C and D) Saquinavir was added to NL4-R3A-infected HF-TOC 6 (C) or 8 (D) days postinfection and each day thereafter, with the
first day of drug addition indicated by the arrow. CD4 thymocyte depletion was assessed at the indicated times. Error bars are from quadruplicate
samples (, P  0.05 by the student’s t test for NL4-R3A with drug relative to NL4-R3A without drug).
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appear to die in a way that does not involve or does not allow
for detection of 7AAD p24 cells.
Infection with NL4-R3A increases apoptosis of p24 and p24
thymocytes. We next determined whether infected or uninfected
thymocytes in NL4-R3A-infected HF-TOC were dying by apop-
tosis. To measure apoptosis, we analyzed active caspase-3 expres-
sion, a downstream effecter caspase of both the intrinsic and
extrinsic apoptosis pathways that is activated in HIV-1-infected
patients (14) and upon exposure of PBMCs and cell lines to
HIV-1 Env (4, 12, 44). For these analyses, only 7AAD-negative
cells in the live cell gate were considered. In mock-infected thy-
mus, 0.3% of cells express active caspase-3 throughout HF-
TOC culture (Fig. 3A). In NL4-R3A-infected thymus, there is a
clear detection of cells which costain for active caspase-3 and p24,
indicating that a fraction of infected cells are likely dying by
apoptosis. Additionally, we observed the significant induction of
bystander apoptosis (7AAD, p24, active caspase-3) in NL4-
R3A- but not NL4-R3B-infected thymus.
An analysis of the total percentage of thymocytes express-
ing active caspase-3 over time indicates that apoptosis is
specifically induced in NL4-R3A-infected thymus relative to
either mock- or NL4-R3B-infected thymus (Fig. 3B). Fur-
thermore, this increase is observable as early as 7 dpi, before
significant thymocyte depletion typically occurs (Fig. 1). The
increase in active caspase-3 expression observed in both
uninfected and infected thymocytes correlates with the ex-
tent of NL4-R3A replication, as measured by FACS detec-
tion of intracellular p24, with a greater number of bystander
apoptotic cells than infected apoptotic cells at all levels of
infection (Fig. 3C). Using annexin-V as an additional marker for
the detection of apoptotic cells, we confirmed the presence of
apoptosis in both bystander and infected apoptotic cells in
NL4-R3A-infected thymus relative to mock-infected thymus
(data not shown).
Immunofluorescent staining of mock- and NL4-R3A-infected
thymus at 12 dpi confirmed the increase in active caspase-3
thymocytes in infected thymus (Fig. 4). Furthermore, the ma-
jority of apoptotic thymocytes do not costain for p24, suggest-
ing they are not productively infected. Together, these data
implicate apoptosis of infected and uninfected thymocytes as
contributors to the rapid thymocyte depletion induced by NL4-
R3A.
T20 and C34 fail to efficiently inhibit ongoing viral replica-
tion but efficiently prevent thymocyte depletion. We next
assessed whether kinetics of viral replication and depletion are
altered by inhibition with saquinavir or the envelope fusion
inhibitors T20 and C34. Drugs were added starting at 7 dpi and
daily thereafter. The doses used for T20, C34, and saquinavir
were sufficient to completely inhibit NL4-R3A infection of
HF-TOC when added at the time of initial infection (data not
shown). In saquinavir-treated HF-TOC, viral replication was
inhibited very rapidly after addition of drug, as assessed by p24
ELISA (Fig. 5A). To address whether unprocessed gag-pol may
limit detection of p24 by ELISA, we tested HIV-1 mutants with
defective gag processing treated with two different detergents
and demonstrated that unprocessed gag was detected as effi-
ciently as processed gag in our ELISA (data not shown), as
previously described (46), suggesting these results were not a
detection bias.
In T20- and C34-treated samples, however, p24 production
from NL4-R3A infection was not significantly inhibited. In
spite of this difference in viral replication, similar rescue of
CD4 thymocytes was observed for all three drugs assessed at
13 dpi, 6 days after the addition of drug (Fig. 5B and C).
Because T20 and C34 do not efficiently inhibit viral replication
but preserve CD4 thymocytes to a level similar to that of
saquinavir, we conclude that fusion-dependent thymocyte de-
pletion plays a major role in NL4-R3A pathogenesis in the
thymus.
Together, these data suggest that HIV-infected thymocytes
die rapidly after de novo infection is inhibited by saquinavir. In
contrast, although T20 and C34 should inhibit de novo in-
fection of thymocytes, viral production is relatively spared
through extended periods of culture. This suggests that T20
and C34 either incompletely inhibit viral spread in HF-TOC
during ongoing infection or that inhibition of fusion preserves
viral production from an infected cellular reservoir.
Apoptosis of both bystander and infected cells is inhibited
by T20. We next assessed whether saquinavir or T20 is capable
of modulating the level of apoptosis observed during infection
with NL4-R3A. Neither drug affected the level of apoptosis in
mock-infected HF-TOC (data not shown). Interestingly, while
viral replication was inhibited more efficiently by saquinavir
than by T20, only T20 reduced apoptosis of both bystander and
HIV-1-infected thymocytes (Fig. 6A). When observed over
multiple experiments with multiple donor thymus tissues,
the frequency of caspase-3 p24 cells was not significantly
changed for saquinavir-treated samples but was notably re-
duced for T20-treated samples relative to no-drug controls
(Fig. 6B). When this analysis was extended to HIV-1-infected
(p24) cells, saquinavir was found to cause a significant in-
crease and T20 a significant decrease in apoptosis relative to
no-drug controls at comparable levels of replication (Fig. 6C).
Since T20 has been shown to inhibit HIV-1 fusion by targeting
both gp41 and gp120 (3, 57), another HIV-1 fusion inhibitor,
C34, which only interacts with gp41, was used to confirm this
finding. Addition of C34 to HIV-1-infected HF-TOC also re-
sulted in a reduction of apoptosis in both p24 and p24
thymocytes (data not shown).
In multiple experiments we observed similar p24 production
in the presence of T20 or C34 compared to no drug treatment
assessed by p24 ELISA, as depicted in Fig. 5A, but a reduced
FIG. 2. Increase in 7AAD thymocytes in NL4-R3A-infected HF-TOC is predominantly in the p24 population. (A) Cells in the scatter-
defined live cell gate were stained for 7AAD to measure dead cells and p24 to measure productively infected cells. Shown are representative plots
for mock-, NL4-R3A-, and NL4-R3B-infected thymus at 9 and 12 dpi. (B) The percentage of 7AAD thymocytes in the live gate for mock-,
NL4-R3A-, and NL4-R3B-infected thymus over time. (, P  0.05 for NL4-R3A trend line relative to mock and NL4-R3B.) (C) The increase in
7AAD cells occurs predominantly in the uninfected (p24) population of the NL4-R3A-infected thymus. The proportion of uninfected
thymocytes (p24 thymocytes) and infected thymocytes (p24 thymocytes) which are 7AAD is shown. (B and C) Data are from seven
independent experiments. (, P  0.05 for p24 trend line relative to p24.)
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percentage of p24 cells measured by FACS analysis, as de-
picted in Fig. 6A. This is likely explained by the massive de-
pletion in no-drug-treated thymus, leading to observed in-
creases in the relative percentage of p24 thymocytes but an
overall equal amount of p24 production compared to T20-
treated samples which have CD4 preservation. Thus, similar
numbers of productively infected (p24) thymocytes per HF-
TOC are detected in T20-treated and no-drug-treated HF-
TOC samples (data not shown). Together, these data suggest
that Env-mediated fusion plays a role in the induction of apop-
FIG. 3. Infection with NL4-R3A increases the frequency of thymocytes expressing active caspase-3. (A) 7AAD-negative live cells were stained
for p24 and active caspase-3. Shown is a representative of seven independent experiments from 9 and 12 dpi for mock-, NL4-R3A-, and
NL4-R3B-infected thymus. (B) NL4-R3A increases the frequency of total thymocytes with active caspase-3 expression (, P  0.05 for NL4-R3A
trend line relative to mock and NL4-R3B.) (C) The increase in active caspase-3 cells in NL4-R3A-infected HF-TOC occurs in both uninfected
(p24) and infected (p24) thymocytes in proportion to the level of NL4-R3A replication. (, P  0.05 for the strength of significance for each
trend line.) (B and C) Data are from seven independent experiments.
FIG. 4. Most caspase-3 thymocytes in NL4-R3A-infected HF-TOC do not express p24. Fragments from mock- and NL4-R3A-infected thymus
at 12 dpi were stained for p24 (green; Fluor 546) and active caspase-3 (red; Fluor 488). Shown is a representative of two independent experiments.
Low (20) and high (60) magnifications are shown. Isotype control antibodies showed no specific signals (data not shown).
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tosis of both bystander and infected thymocytes in the NL4-
R3A-infected thymus.
DISCUSSION
In this study, we characterize the depletion of CD4 thymo-
cytes in the intact thymus by a highly pathogenic envelope
obtained from a rapid progressor at the time of transmission.
Our goal is to understand the mechanisms of thymocyte death
in the HIV-infected thymus organ. We observed a replication-
and Env-dependent depletion of CD4 thymocytes (Fig. 1).
During depletion with NL4-R3A, the percentage of thymo-
cytes which stain with 7AAD increases, predominantly in the
FIG. 5. Prevention of thymocyte depletion in T20- and C34-treated HF-TOC in spite of sustained replication. (A to C) NL4-R3A-infected
HF-TOC was treated with C34, T20, or saquinavir from 7 dpi for 6 days. Arrows indicate the day of drug addition. (A) Viral load was quantitated
by ELISA detection of Gag antigen in the HF-TOC supernatant on the indicated days. Error bars are derived from triplicate samples. (, P  0.05
by the student’s t test for drug treatment relative to no drug.) (B and C) Similar percentages of CD4 thymocyte protection after T20, C34, and
saquinavir treatment were detected 6 days after drug treatment by CD4 and CD8 staining. Error bars are derived from triplicate samples. Shown
is a representative of three independent experiments. (, P  0.05 by the student’s t test relative to no drug.)
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FIG. 6. Apoptosis in NL4-R3A-infected HF-TOC is inhibited by T20. (A) NL4-R3A-infected HF-TOC was treated with saquinavir or T20 at
6 dpi for up to 4 days. Thymocytes were stained with 7AAD, p24, and active caspase-3. Shown is a representative of five experiments for 7AAD
live cells 3 days after drug addition. (B) The frequency of bystander apoptosis (percent caspase-3 p24) was determined for each experimental
treatment. The combined data for all time points from five independent experiments are shown with standard error bars. (mean percentage p24
of 14% for no drug, 4.5% for saquinavir, and 5.7% for T20). (C) Saquinavir increased, but T20 decreased, apoptosis of infected thymocytes. To
compare HF-TOC with similar levels of replication, only samples with less than 7% p24 were considered for “no drug” treatment (mean percent
p24 of 4.4% for no drug, 4.5% for saquinavir, and 5.7% for T20). (, P  0.05 by the student’s t test relative to no drug for panels B and C.)
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uninfected (p24) population (Fig. 2). Prior to and concurrent
with this depletion, we detected a significant increase in the
frequency of thymocytes expressing both active caspase-3 and
annexin-V, suggesting that they are undergoing apoptosis (Fig.
3 and 4; data not shown). Notably, this apoptosis is detected in
productively infected (p24) thymocytes as well as in unin-
fected (p24) thymocytes. We show that induction of apoptosis
is preferentially observed in the NL4-R3A-infected thymus but
not in the less pathogenic NL4-R3B-infected thymus (Fig. 3).
Although T20- and C34-treated HF-TOC during ongoing in-
fection showed higher HIV-1 replication levels than saquina-
vir-treated HF-TOC, T20 and C34 were noticeably better at
blocking the frequency of apoptosis in both uninfected and
infected thymocytes and efficiently protected total CD4 thy-
mocyte depletion in spite of high levels of HIV-1 (Fig. 5 and 6).
In sum, these data implicate envelope-mediated fusion in the
induction of apoptosis and thymocyte depletion during infec-
tion of HF-TOC with the pathogenic NL4-R3A virus. These
data are the first to describe envelope-specific and fusion-
dependent induction of apoptosis in a relevant lymphoid organ
model.
From previous studies it is still unclear whether HIV-1 in-
fection in lymphoid organs depletes only infected cells or both
infected and uninfected bystander cells (6, 30, 39, 48). Our data
suggest that direct depletion of infected thymocytes is clearly
involved, as inhibition of HIV-1 infection during its peak levels
of replication and depletion halts further thymocyte depletion
(Fig. 1). The mechanism of this “lytic” depletion remains un-
clear, but it does not appear to involve a cell which stains for
both p24 and 7AAD (Fig. 2). Notably, we also observe signif-
icant induction of apoptosis in “bystander” p24 thymocytes
and in p24 thymocytes (Fig. 3). Together, our data suggest a
model for thymocyte depletion induced by highly pathogenic
HIV-1 isolates such as NL4-R3A. During NL4-R3A replica-
tion, Env expressed on virus or infected cells is likely capable
of binding and fusing uninfected cells. Bystander cells which
encounter the R3A Env are triggered to express active caspase-3
and eventually die by apoptosis (Fig. 3), consistent with find-
ings from in vitro studies showing Env can trigger caspase-3-
dependent cell death (4, 12, 44). Infected cells are also ob-
served to express active caspase-3 (Fig. 3), suggesting apoptosis
as one means of infected cell death. Intriguingly, T20 reduces
apoptosis of infected cells (Fig. 5 and 6), suggesting autologous
Env fusion may contribute to pathogenesis. Less fusogenic Env
proteins, such as R3B, are less capable of inducing apoptosis
(Fig. 3), perhaps helping to explain their lower level of activity
in thymocyte depletion.
Advantageously, our study does not involve prolonged cul-
ture of isolated thymocytes outside of the thymic organ before
analysis, which could enhance their susceptibility to death.
However, the major mechanistic limitation to this study is the
inability to precisely determine the relative life span and even-
tual fate of individual cells. For example, it is difficult to as-
certain how long an infected or an apoptotic cell resides as a
single cell in the thymus before engulfment or disintegration,
even though estimates from other studies suggest a half-life of
12 to 36 h for apoptotic cells (2). Rather, our study relies on a
series of snapshots over time. This limitation prevents us from
attributing a contributory or a predominant role to apoptosis,
relative to other cell death pathways, in the context of overall
thymocyte depletion.
When added prior to or together with HIV-1 infection in
HF-TOC, saquinavir, T20, and C34 all efficiently prevent in-
fection (E. Meissner, L. Zhang, and L. Su, unpublished re-
sults). Interestingly, viral production in HF-TOC with ongoing
infection was efficiently suppressed by saquinavir but not by
T20 or C34 (Fig. 5 and 6). In the presence of high levels of
HIV-1 replication, T20 and C34 both efficiently prevent HIV-
1-induced thymocyte depletion, suggesting a protective effect
of T20 and C34 on a cellular reservoir remaining in the thymic
fragment that has yet to be characterized. This higher level of
replication may explain the observation that although it is
more efficient at blocking bystander and infected cell apoptosis
(Fig. 6), T20 is not noticeably better than saquinavir at block-
ing overall depletion of CD4 thymocytes (Fig. 5). One pos-
sible explanation is that while T20 reduces the level of apop-
tosis, it may allow for prolonged survival of infected cells,
leading to elevated HIV-1 cells and virions, which may con-
tribute to elevated levels of fusion-independent cell killing.
Together, these data strongly suggest the contribution of en-
velope-induced apoptosis to the depletion of infected thymo-
cytes.
How exactly does the R3A Env mediate thymocyte depletion
in the thymus? It is likely that the high levels of replication
supported by the R3A Env leads to thymocyte depletion
through a combination of direct and indirect effects, including
but not limited to the direct and bystander killing discussed
above. Interestingly, at levels of infection that were compara-
ble to those of NL4-R3A, we did not detect an increase in
apoptosis by NL4-R3B, suggesting that the depletion of thy-
mocytes is specifically mediated in part by the R3A Env pro-
tein, which shows enhanced affinity for CXCR4 and cytopath-
icity for T cells in vitro (37, 38). Whether CXCR4 affinity is
linked to the induction of apoptosis, as has been previously
observed (27, 54), remains to be elucidated. Interestingly,
when 200 nM AMD3100 was added to HF-TOC with ongoing
R3A HIV-1 infection, we observed little or no inhibition of
HIV replication or pathogenesis (data not shown). This may be
due to the increased resistance of R3A to AMD3100 or to the
fact that R3A can use CCR5 as well as CXCR4 in HF-TOC
(37). Future experiments will focus on possible inhibition of
apoptosis by blockade of CXCR4-Env interactions in NL4-
R3A-infected HF-TOC.
Because addition of AT-2 inactivated virions and transfer of
supernatant from NL4-R3A-infected thymus to uninfected
thymus in the presence of HIV-1 inhibitors is unable to reca-
pitulate thymic pathogenesis (E. Meissner and L. Su, unpub-
lished results), productive infection and cell-associated Env is
likely essential for pathogenesis (1, 20, 50). Alternatively and
additionally, other HIV-1 or host factors induced during
HIV-1 infection may contribute to Env-mediated thymocyte
depletion. Further study of NL4-R3A in HF-TOC should help
elucidate viral and cellular mechanisms that result in rapid
depletion of thymocytes.
The HF-TOC thymus model, an intact human lymphoid
organ with multiple cell types in physiological orientation, is an
ideal model for investigating acute HIV-1 infection in lym-
phoid organs. Our data here contrast with studies in cell lines
in vitro which, like our study, show that cytopathicity is depen-
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dent on fusion of envelope but, unlike our study, do not detect
any bystander cell death (35). These disparities highlight the
differences that likely exist between mechanisms of death in
single-cell cultures and in complex, tightly knit lymphoid or-
gans that contain a variety of interacting cell types. The fact
that T20 reduces apoptosis of cells productively infected with
HIV-1 raises a number of potential clinical implications. En-
couragingly, these data do indicate that C34 and T20 are ca-
pable of blocking most CD4 T-cell depletion in an intact
lymphoid organ. However, protection of HIV-1-infected cells
from apoptosis and depletion, even transiently, may lead to
enhanced HIV-1 latency and/or a viral reservoir in fusion in-
hibitor-treated patients. It will be of importance to investigate
the effect of T20 on the survival and persistence of HIV-1
cells in these patients.
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